163 related articles for article (PubMed ID: 17297610)
1. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
Takahashi Y; Miyoshi Y; Morimoto K; Taguchi T; Tamaki Y; Noguchi S
J Cancer Res Clin Oncol; 2007 Aug; 133(8):501-9. PubMed ID: 17297610
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
4. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
5. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Nitz U; Gluz O; Huober J; Kreipe HH; Kates RE; Hartmann A; Erber R; Moustafa Z; Scholz M; Lisboa B; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Weiss E; Böhmer S; Kreienberg R; Du Bois A; Sattler D; Thomssen C; Kiechle M; Jänicke F; Wallwiener D; Harbeck N; Kuhn W
Ann Oncol; 2014 Aug; 25(8):1551-7. PubMed ID: 24827128
[TBL] [Abstract][Full Text] [Related]
6. Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Takamura Y; Kobayashi H; Taguchi T; Motomura K; Inaji H; Noguchi S
Int J Cancer; 2002 Mar; 98(3):450-5. PubMed ID: 11920599
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
8. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
Piedbois P; Serin D; Priou F; Laplaige P; Greget S; Angellier E; Teissier E; Berdah JF; Fabbro M; Valenza B; Herait P; Jehl V; Buyse M
Ann Oncol; 2007 Jan; 18(1):52-57. PubMed ID: 17047001
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.
Egawa C; Motomura K; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Inaji H; Koyama H; Noguchi S
Breast Cancer Res Treat; 2003 Mar; 78(1):45-50. PubMed ID: 12611456
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Egawa C; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2001 Jul; 95(4):255-9. PubMed ID: 11400119
[TBL] [Abstract][Full Text] [Related]
12. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Miyoshi Y; Ando A; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2002 Jan; 97(1):129-32. PubMed ID: 11774254
[TBL] [Abstract][Full Text] [Related]
13. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.
Asakawa H; Koizumi H; Koike A; Takahashi M; Wu W; Iwase H; Fukuda M; Ohta T
Breast Cancer Res; 2010; 12(2):R17. PubMed ID: 20205718
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
15. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.
Ohno S; Chow LW; Sato N; Masuda N; Sasano H; Takahashi F; Bando H; Iwata H; Morimoto T; Kamigaki S; Nakayama T; Nakamura S; Kuroi K; Aogi K; Kashiwaba M; Yamashita H; Hisamatsu K; Ito Y; Yamamoto Y; Ueno T; Fakhrejahani E; Yoshida N; Toi M
Breast Cancer Res Treat; 2013 Nov; 142(1):69-80. PubMed ID: 24122389
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer.
Hirano A; Shimizu T; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Aiba M; Ogawa K
Anticancer Res; 2008; 28(6B):4137-42. PubMed ID: 19192673
[TBL] [Abstract][Full Text] [Related]
19. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
Alamgeer M; Ganju V; Kumar B; Fox J; Hart S; White M; Harris M; Stuckey J; Prodanovic Z; Schneider-Kolsky ME; Watkins DN
Breast Cancer Res; 2014 Apr; 16(2):R44. PubMed ID: 24762066
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
